Last checked at 16 Apr 2024 09:48
LONDON BROKER RATINGS: RBC raises Admiral; Barclays cuts Phoenix Group
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat
AZN Share
Trades18,291
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
11,988.00
Bid:
12,016.00
Ask:
12,020.00
Change:
-38.00 (-0.32%)
Spread:
4.00 (0.033%)
Open:
12,070.00
High:
12,144.00
Low:
11,882.00
Prev. Close:
12,026.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.AstraZeneca to raise ?2.7bn for cancer collab, bond repayment
Fri, 29th Mar 2019 08:03
(Sharecast News) - AstraZeneca plans to raise $3.5bn (£2.7bn) in a share placing to fund a new cancer drug collaboration with Japan's Daiichi Sankyo and repay some of its bonds.The collaboration is to accelerate the development of the Japanese company's novel HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan, expanding the treatment across breast and other cancers.Astra will pay $1.35bn of the net placing cash to Daiichi Sankyo, of which half will be paid up-front and the rest in 12 months' time. There are also expected to be roughly $1bn of approval and sales-related contingent milestone payments starting from next year until 2022.Trastuzumab deruxtecan is currently in development for the treatment of multiple HER2-expressing cancers, including breast and gastric cancer, and in patients with HER2-low expression.In 2017, the US regulator awarded the conjugate was breakthrough therapy designation for the treatment of patients with HER2-positive, locally-advanced or metastatic breast cancer who have been treated with trastuzumab and pertuzumab and have disease progression after trastuzumab emtansine.Astra chief executive Pascal Soriot said: "We believe that trastuzumab deruxtecan could become a transformative new medicine for the treatment of HER2-positive breast and gastric cancers."In addition, it has the potential to redefine breast cancer treatment as the first therapy for HER2-low expressing tumours. It also has the potential to treat other HER2-mutated orHER2-overexpressing cancers, including lung and colorectal cancers. We are proud to be working with Daiichi Sankyo, a long-term collaborator of AstraZeneca in other disease areas."Another $1bn of the placing funds will be used to pay off its 1.95% bonds due on 18 September 2019, with the remainder of the placing proceeds held as cash to help strengthen the balance sheet.
More News
16 Apr 2024 09:30
Boehringer replaces Bayer as Germany's largest drugmaker on Jardiance gains
INGELHEIM, Germany, April 16 (Reuters) - Boehringer Ingelheim on Tuesday overtook Bayer as Germany's largest drugmaker when the unlisted company reported a currency-adjusted gain in 2023 pharmaceutical sales of 10.3% to 20.8 billion euros ($22.11 billion).
Read more16 Apr 2024 08:39
AstraZeneca's hails Imfinzi survival data on cancer form
(Alliance News) - AstraZeneca PLC on Tuesday said that its immunotherapy Imfinzi showed positive survival rate in people with advanced biliary tract cancer.
Read more12 Apr 2024 12:55
EU regulator rules out link between weight-loss drugs and suicidal thoughts
April 12 (Reuters) - The European Union drug regulator found no evidence that a class of diabetes and weight-loss drugs such as Novo Nordisk's hugely popular Wegovy, are linked to suicidal thoughts, it said on Friday, ending a nine-month probe.
Read more11 Apr 2024 18:51
AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition
Policy approved with two-third of votes in favour
*Read more11 Apr 2024 17:13
FTSE 100 edges lower as financials drag
Lok'nStore surges to all-time high after buyout by Shurgard
*Read more11 Apr 2024 17:07
Banks weigh down Europe's STOXX 600 after ECB signals rate cuts
Outlook hike sends Ambu shares up
*Read more11 Apr 2024 15:56
London close: Stocks finish lower as ECB stands pat
(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.
Read more11 Apr 2024 11:50
LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision
(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.
Read more11 Apr 2024 08:56
TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023
(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.
Read more11 Apr 2024 08:54
LONDON MARKET OPEN: European markets mixed ahead of ECB decision
(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.
Read more11 Apr 2024 07:49
LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance
(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.
Read more11 Apr 2024 07:20
AstraZeneca to hike 2024 dividend by 7%
(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.
Read more8 Apr 2024 08:36
TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris
(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.
Read more8 Apr 2024 07:43
LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack
(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.
Read more